Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Immunotherapy strategies for multiple myeloma: the present and the future.

Locke FL, Nishihori T, Alsina M, Kharfan-Dabaja MA.

Immunotherapy. 2013 Sep;5(9):1005-20. doi: 10.2217/imt.13.97. Review.

2.
3.

Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma.

Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH.

Biol Blood Marrow Transplant. 2010 Aug;16(8):1122-9. doi: 10.1016/j.bbmt.2010.02.015. Epub 2010 Feb 21.

4.

Emerging therapies for multiple myeloma.

Podar K, Tai YT, Hideshima T, Vallet S, Richardson PG, Anderson KC.

Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278 . Review.

5.

A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97.

Vesole DH, Zhang L, Flomenberg N, Greipp PR, Lazarus HM, Huff CA; ECOG Myeloma and BMT Committees.

Biol Blood Marrow Transplant. 2009 Jan;15(1):83-91. doi: 10.1016/j.bbmt.2008.10.030. Erratum in: Biol Blood Marrow Transplant. 2009 Oct;15(10):1346. Huff, Carol A [added].

6.

Survival from multiple myeloma in England and Wales up to 2001.

Schey S.

Br J Cancer. 2008 Sep 23;99 Suppl 1:S113-5. doi: 10.1038/sj.bjc.6604608. No abstract available.

7.
8.

Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.

Georges GE, Maris MB, Maloney DG, Sandmaier BM, Sorror ML, Shizuru JA, Lange T, Agura ED, Bruno B, McSweeney PA, Pulsipher MA, Chauncey TR, Mielcarek M, Storer BE, Storb R.

Biol Blood Marrow Transplant. 2007 Apr;13(4):423-32. Epub 2007 Feb 1.

Supplemental Content

Support Center